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MetabolismDominant mutations in the human insulin gene can lead to pancreatic b-cell dysfunction and diabe-
tes mellitus due to toxic folding of a mutant proinsulin. Analogous to a classical mouse model (the
Akita mouse), this monogenic syndrome highlights the susceptibility of human b-cells to endoretic-
ular stress due to protein misfolding and aberrant aggregation. The clinical mutations directly or
indirectly perturb native disulﬁde pairing. Whereas the majority of mutations introduce or remove
a cysteine (leading in either case to an unpaired residue), non-cysteine-related mutations identify
key determinants of folding efﬁciency. Studies of such mutations suggest that the evolution of insu-
lin has been constrained not only by its structure and function, but also by the susceptibility of its
single-chain precursor to impaired foldability.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Insulin plays a central role in the regulation of vertebrate
metabolism. The mature hormone, the post-translational product
of a single-chain precursor, is a globular protein containing two
chains, A (21 residues) and B (30 residues). Advances in human
genetics over the past ﬁve years have identiﬁed dominant muta-
tions in the insulin gene associated with diabetes mellitus (DM)
(for reviews, see [1–3]). This syndrome arises from the toxic mis-
folding: the clinical mutations impair the folding of proinsulin in
the endoplasmic reticulum (ER) of pancreatic b-cells [4,5]. Origi-
nally described in relation to neonatal-onset DM [6–9], DM may
also present in childhood [10] or early adulthood [11]. Age of onset
is proposed to reﬂect mutational differences in the degree of im-
paired folding and its cellular consequences [5,12]. Phenotypic var-
iation may also arise due to polygenic differences in b-cell
susceptibility to ER stress [13].
Patients with the mutant proinsulin syndrome are heterozy-
gous. Although expression of one wild-type insulin allele would
in other circumstances be sufﬁcient to maintain metabolic homeo-
stasis, studies of a corresponding mouse model (the Akita mouse
[14–16]) have demonstrated that misfolding of the variant proin-
sulin perturbs the biosynthesis of wild-type insulin [17,18]. In asurvey of human mutations similar perturbations in trans have
been demonstrated in b-cell lines [4,5,12]. Impaired b-cell secre-
tion is associated with ER stress, distorted organelle architecture,
and eventual cell death [19,20]. These ﬁndings have stimulated re-
newed interest in the biosynthesis of insulin [21–23] and the struc-
tural basis of disulﬁde pairing [24–29]. The foundational
importance of this problem and its clinical relevance have moti-
vated construction of novel molecular reagents and animal models
[30–33]. Such studies have led in parallel to an enhanced under-
standing of structure–function relationships [13] and cellular
mechanisms of proinsulin folding and insulin biosynthesis [1].
Clinical mutations in the insulin gene provide probes into evolu-
tionary constraints shared by a family of single-chain factors (such
as mammalian insulin-like growth factors) and in part by a super-
family of invertebrate insulin-like proteins [34–36]. Such relation-
ships have motivated studies of the mitogenic properties of
proinsulin, revealing preferential signaling through the A isoform
of the insulin receptor (IR) [35]. Although beyond the scope of this
review, these activities may be relevant to carcinogenesis [37].
Therapeutic use of proinsulin in the treatment of human DM has
been investigated but would have unclear clinical beneﬁts [38].
2. Biosynthesis of insulin
The insulin gene encodes a single-chain precursor polypeptide,
designated preproinsulin (Fig. 1A, top). The signal peptide (gray bar
in Fig. 1A) is cleaved on translocation into the ER to yield proinsulin.
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connecting domain (black in Fig. 1A) between the C-terminal resi-
due of the B domain (blue) and N-terminus of the A domain (red)
[39]. Its folding in the ER is coupled to the speciﬁc pairing of three
cystines (Fig. 1A, center). The disulﬁde bridges (A6–A11, A7–B7,
and A20–B19; shown in gold in Fig. 1B) contribute to protein sta-
bility and biological activity [27,40–48]. The solution structure of
proinsulin as an engineered monomer consists of a folded insu-
lin-like moiety and a ﬂexible C domain (black segment in Fig. 1B)
[49]. The overall structure is in accordance with prior biochemical
evidence [50–55]. The structure, stability, and receptor-binding
activity of insulin (Fig. 1A, bottom) require maintenance of each
disulﬁde bridge [27,40–42,44–48]. Conserved among insulin-re-
lated ligands, the cystines provide interior struts (A19–B20 and
A6–A11) and an external staple between chains (A7–B7). Insulin
disulﬁde isomers exhibit molten structures of marginal stability
and low activity [56–58].
Proinsulin binds only weakly to the insulin receptor; proteolytic
processing liberates the mature hormone [22,38]. On transit
through the Golgi apparatus (GA) and immature secretory granules
[59], the C-peptide is excised by prohormone convertases [60],
which cleave conserved dibasic sites ﬂanking the C domain (BC
and CA junctions; green in Fig. 1A, B). Insulin is stored as Zn2+-sta-
bilized hexamers as microcrystalline arrays [61–63] within spe-
cialized secretory granules [64]. The hexamers dissociate on
secretion into the portal circulation, enabling the circulating hor-
mone to function as a Zn2+-free monomer. Because the insulin
monomer is exquisitely susceptible to ﬁbrillation at millimolar
concentration and body temperature [65], its zinc-mediated
assembly within b-cells may represent a defense against toxic mis-
folding [66] during storage in the secretory granule [23]. Evidence
that such assembly contributes to insulin storage and efﬁcient
secretion has recently been obtained through studies of a mouse
model lacking the b-cell zinc transporter [67].
Although insulin biosynthesis occurs via a single-chain precur-
sor, its chemical synthesis has traditionally employed isolated A-
and B-chain peptides (for review see [68]). The success of insulinFig. 1. Biosynthesis of proinsulin. (A) Pathway begins with preproinsulin (top): signal pe
CA junction (green), and A-domain (red). Speciﬁc disulﬁde pairing in the ER yields n
convertases PC1 and PC2) releases insulin and C-peptide (bottom). (B) Solution structure
A- and B-domains are shown in red and blue, respectively; C-domain contains a nascent
solution structure exploited an engineered monomer (DKP-proinsulin) as characterized
depicts a representative member of an ensemble of solution structures (Protein Databanchain combination implies that chemical information required
for folding is contained within the sequences of the A- and B do-
mains [69,70]. A variety of analogs have been prepared by this pro-
tocol, facilitating their pharmaceutical development for treatment
of DM [71,72]. Despite the general robustness of insulin chain com-
bination, synthesis of certain analogs has been confounded by low
yields [26,73–79]. Such synthetic failures provide models of im-
paired folding, providing insight into structural mechanisms that
underlie the mutant proinsulin syndrome.
3. Mechanism of disulﬁde pairing
Oxidative folding of globular proteins has traditionally been
investigated by chemical trapping of populated disulﬁde interme-
diates [80]. Such studies of proinsulin and related polypeptides –
foreshortened single-chain analogs (mini-proinsulin [81]) and
insulin-like growth factors – are notable for the transient accumu-
lation of one- and two-disulﬁde intermediates [24,25,82]. Succes-
sive steps of partial folding deﬁne a series of trajectories on a
sequence of free-energy landscapes (Fig. 2A). Each landscape
underlies the dynamics of an ensemble of accessible polypeptide
conformations in the presence of a speciﬁc subset of disulﬁde
bridges. The landscapes proceed from shallow to steep, enabling
the folding chain to acquire structure stepwise on successive disul-
ﬁde pairing. The preferred sequence of disulﬁde intermediates, as
deﬁned by chemical trapping, thus corresponds to a progression
of multiple folding trajectories on funnel-shaped landscapes. This
perspective extends the classical disulﬁde-centered view of pro-
tein-folding intermediates [83] to encompass general biophysical
paradigms of protein folding [84–86].
Although refolding studies of proinsulin are limited by aggrega-
tion (imposing a requirement for pH conditions >9, confounding
interpretation [87]), the disulﬁde pathways of mini-proinsulin
and IGF-I are well characterized near neutral pH
[24,25,40,43,82,88,89]. A structural pathway is suggested by spec-
troscopic studies of equilibrium models (Fig. 2B) [27,40–42,44–
48,90]. In this pathway a key role is played by initial formationptide (gray), B-domain (blue), dibasic BC junction (green), C-domain (black), dibasic
ative proinsulin (middle panels). BC- and CA cleavage (mediated by prohormone
of proinsulin: insulin-like moiety and disordered connecting peptide (dashed line).
a-helical turn near the CA junction [49]. Cystines are labeled in yellow boxes. The
by multi-dimensional 1H–13C–15N NMR. Panel A is adapted from Ref [13] panel B
k entry 2KQP).
Fig. 2. Energy landscape paradigm. (A) Successive disulﬁde pairing enables a sequence of folding trajectories on ever-steeper funnel-shaped free-energy landscapes. (B)
Preferred pathway of disulﬁde pairing. Initial formation of cystine A20–B19 (left) is directed by a nascent hydrophobic core comprising the central B-domain a-helix (residues
B9–B19), part of the C-terminal B-chain b-strand (B24–B26), and part of the C-terminal A-domain a-helix (A16–A20). Alternative pathways mediate successive disulﬁde
pairing (middle panel) leading in turn to the native state (right). The mechanism of disulﬁde pairing is perturbed by clinical mutations associated with a monogenic syndrome
of DM due to toxic misfolding of the variant proinsulin in the ER. Figure is adapted from Ref. [49]; panel A is adapted from an image kindly provided by J. Williamson.
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within a cluster of conserved aliphatic and aromatic side chains
in the hydrophobic core to connect the C-terminal a-helix of the
A domain to the central a-helix of the B domain [57,58,75]. Be-
cause cystine A20–B19 is the only one-disulﬁde species to accumu-
late in the refolding of mini-proinsulin and IGF-I [24,25,89], its
initial pairing is proposed to contribute to the stabilization of a
speciﬁc folding nucleus [27,90,91].
The structural role of cystine A20–B19 in populated one- and
two-disulﬁde intermediates motivated construction of analogs
(of insulin, mini-proinsulin, and IGF-I) containing pairwise substi-
tution of the other cysteines by Ala or Ser [27,40–48]. Such analogs
exhibit attenuated a-helix content. Nucleation of native-like struc-
ture was observed in a disulﬁde-linked peptide fragment of IGF-I
containing cystine A20–B19: at low temperature the disulﬁde
bridge native tethers a-helices within a cluster of non-polar side
chains resembling the native core [27]. Mutations within this
A20–B19-associated subdomain impair disulﬁde pairing in insulin
chain combination and the biosynthesis of single-chain precursors
in Saccharomyces cerevisciae [44,77,91–93].
1H NMR spectra of the above equilibrium models exhibit a pro-
gressive increase in chemical-shift dispersion with successive
disulﬁde pairing, suggesting stepwise stabilization of structure.
These ﬁndings are in accordance with the landscape perspective
[40,90]. After A20–B19 pairing, folding can proceed through multi-
ple alternative channels. Folding of mini-proinsulin near neutralpH exhibits subsequent rapid formation of cystine A7–B7 (lower
pathway in Fig. 2B) or slow pairing of A6–A11 (upper pathway).
Although it is not intuitive why pairing of cysteines distant in
the sequence (A7 and B7) is favored relative to pairing of proxi-
mate cysteines (A6 and A11), spectroscopic studies have demon-
strated that removal of cystine A7–B7 (by pairwise substitution)
destabilizes the structure of insulin more markedly than does re-
moval of A6–A11 [91]. These ﬁndings suggest that nascent struc-
ture in the one-disulﬁde [A20–B19] intermediate either more
effectively aligns CysA7 and CysB7 or more signiﬁcantly impairs
pairing of CysA6 and CysA11. Either of these on-pathway two-disul-
ﬁde intermediate may interconvert with non-native disulﬁde iso-
mers as off-pathway kinetic traps (central panel of Fig. 2B).
The hazard of competing traps in the refolding of proinsulin is
suggested by the refolding of an homologous polypeptide (IGF-I)
to form native and non-native disulﬁde isomers as alternative
ground states (native IGF-I and IGF-swap) [24,82]. Containing
respective pairings [A20–B19, A7–B7, A6–A11] (native) and
[A20–B19, A6–B7, A7–A11] (swap), the isomers exhibit similar core
structures near the shared A20–B19 disulﬁde bridge [24,94]. The
relative stabilities of these isomers in a mini-IGF model is con-
trolled by the N-terminal segment of the B domain [95,96].
Although proinsulin has a unique disulﬁde-speciﬁc ground state,
this and a second isomer (pairings [A20–B19, A11–B7, A6–A7])
readily form following disulﬁde exchange in the presence of a
chemical denaturant [57]. Whereas the stability of IGF-swap is
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insulin and proinsulin are molten globules of marginal stability
[58].
Evidence for the pathological relevance of non-native disulﬁde
isomers of proinsulin and related polypeptides has been obtained
in eukaryotic cell culture [20,26,97–99]. An assay for non-native
isomers has been developed based on native polyacrylamide gel
electrophoresis. This assay exploits the slower mobilities of mis-
folded proteins, presumably reﬂecting their less compact struc-
tures. Formation of non-native proinsulin isomers has thus been
observed on transfection of expression constructs in both S. cerevis-
ciae and rodent neurosecretory cell lines. Although non-native iso-
mers are generally not secreted, amino-acid substitutions in
human proinsulin can enhance the fraction of mispairing in the
ER [98,99]. Because propensity to misfold in this assay does not
correlate with effects of the substitutions on thermodynamic sta-
bility in vitro, its mechanism is not well understood.
Studies of proinsulin variants containing substitutions or dele-
tions in the N-terminal segment of the B chain suggest that the
contribution of speciﬁc side chains to foldability may not be appar-
ent in the native state [100]. We imagine that the substituted side
chains perturb the relative stabilities or kinetic accessibility of
disulﬁde intermediates disproportionately to their effects on the
native state, once achieved. Alternatively, it is possible that these
residues contribute to interactions of the nascent polypeptide with
ER chaperones and the oxidative machinery of disulﬁde pairing
[101]. The ER of b-cells may contain a lineage-speciﬁc set of chap-
erones and foldases required in combination for insulin biosynthe-
sis. Deﬁning such an ‘‘ER proteome’’ of b-cell-speciﬁc foldases
represents a major goal of current studies. Altered ER proteomes
in non-neurosecretory cell lines is likely to underlie their impaired
ability to support the efﬁcient folding and secretion of proinsulin
[102].
Remarkably, mini-proinsulin (which refolds in vitro more efﬁ-
ciently than proinsulin [103]) misfolds in S. cerevisciae to form a
metastable disulﬁde isomer as the predominant product. This
non-native protein is secreted, indicating that its globular structure
can resemble a native state sufﬁciently to fulﬁll quality-control
checkpoints. Quantitative misfolding of mini-proinsulin in yeast
demonstrates that the ER folding machinery of a eukaryotic cell
can selectively target folding into a non-ground-state conforma-
tion. It would be of future interest to characterize this alternative
pairing scheme and determine the extent of structural resem-
blance to the native fold. Because the aberrant protein is not de-
graded prior to exit through the ER and GA, mini-proinsulin
provides an example of ‘‘stealth’’ misfolding, leading to secretion
of a protein caught in a kinetic trap.4. Diabetes-associated mutations
The majority of mutations in the insulin gene lead to permanent
neonatal-onset DM [8]. Impaired b-cell function develops prior to
maturation of the immune system and so presents as an auto-anti-
gen negative form of apparent Type 1 DM. This presentation may
be due to mutations in genes other than the insulin gene [104].
The most common cause is a heterozygous activating mutation
in a subunit of the b-cell voltage-gated potassium channel, either
KCNJ11 (encoding the Kr6.2 subunit) or ABCC8 (encoding the Sur1
subunit) [105,106]. The resulting diabetic phenotype may be tran-
sient or permanent. In favorable cases recognition of this syndrome
enables patients to be treated with oral agents that inhibit the
channel (sulfonylureas) rather than insulin [104].
Dominant mutations in the insulin gene deﬁne the second most
common genetic cause of permanent neonatal DM [6–8,10]. Such
mutations occur in each region of preproinsulin: its signal peptide,A-, B- and C domains (Fig. 1A). The majority of such mutations re-
sult in the addition or removal of a cysteine, leading in either case
to an odd number of potential pairing sites. This imbalance leads in
general to misfolding and aggregation [4,5,12]. Remarkably, the
catalogue of human mutations encodes the same ‘‘Akita’’ substitu-
tion (CysA7? Tyr) as in the Ins2 gene of theMody4mouse [14–16];
this dominant murine substitution thus provides an attractive
model of progressive postnatal b-cell failure [18–20]. The variant
murine proinsulin in vitro undergoes partial unfolding with in-
creased aggregation [107]. Analogous perturbations were charac-
terized in human insulin- and proinsulin analogs lacking cystine
A7–B7 [47,91]. Heterozygous expression of a variant Ins2 allele
encoding CysA6? Ser (identiﬁed in an N-ethyl-N-nitrosourea
screen) likewise induces DM [108].
The identiﬁcation of identical human and murine mutations at
position A7 suggests that the pathogenesis of neonatal DM in these
patients is likewise similar to that of the Akita mouse, which has
been extensively characterized [14–16,18–20]. Although the
mechanism of b-cell degeneration in the Akita mouse remains
incompletely understood, its b-cells exhibit an early defect in the
folding and trafﬁcking of both wild-type and variant proinsulins.
Such impaired biosynthesis is accompanied by elevated markers
of ER stress, electron-dense deposits in abnormal ER and GA, mito-
chondria swelling, and progressive loss of b-cell mass [18–20].
Extension of such ﬁndings to human variants has been aided by
the construction of innovative ﬂuorescent proinsulin fusion pro-
teins and their use in cell lines and transgenic mice as probes of
subcellular localization and aggregation [30–33].
Biochemical studies of clinical variants in b-cells or neurosecre-
tory cell lines have revealed perturbations in disulﬁde pairing,
which range from severe or mild depending on the site of mutation
and the properties of the substituted side chain [1–3]. Whereas an
odd number of cysteines presumably induces a severe block to
folding, better-tolerated mutations present later in life as auto-
antibody-negative presumed Type 1 DM or Type 2 DM. One such
mutation, presenting in the second decade as maturity-onset dia-
betes of the young (MODY), is due to substitution of ArgB22 by
Gln. This mutation alters a solvent-exposed site in the B20–B23
b-turn not required for receptor binding [6–8,10]. DM presenting
in the third decade of life is associated with substitution of PheB24
by Ser [109]. This mutation causes only a mild impairing of recep-
tor binding [110] but like GlnB22 imposes ER stress at a level inter-
mediate between over-expression of wild-type proinsulin and
neonatal variants [5]. Chronic elevation of moderate ER stress in
b-cells presumably leads to a slow but progressive loss of b-cell
mass.
Evidence is accumulating that subtle perturbations of insulin
biosynthesis (due either to variant insulin genes or mutations in
the ER folding machinery) may contribute to the pathogenesis of
non-syndromic Type 2 DM in humans [111,112] as in the Akita
mouse [17,113]. A newly recognized biophysical contribution to
such b-cell dysfunction is ‘‘molecular crowding’’ in the ER due to
over-expression of nascent proinsulin in the face of peripheral
insulin resistance [114], a concept that may have therapeutic
implications [33].
Mutations in the insulin gene unassociated with the defective
folding of proinsulin can also be associatedwith adult-onset pheno-
types of variable penetrance [115]. The diversity of genetic syn-
dromes reﬂects a range of molecular mechanisms in accord with
Murphy’s Law of genetics. Classical insulinopathies (LeuA3 and
LeuB25), for example,markedly perturb receptor binding [109], lead-
ing to reduced clearance and hencemutant hyperinsulinemia [110].
Substitution of HisB10 by Asp by contrast would enhance the recep-
tor-binding activity of the variant insulin if secreted [116], butwith-
in b-cells the substitution leads to aberrant sorting of the mutant
proinsulin to a constitutive (i.e., non-glucose-regulated) granule
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convertases, the patients exhibit mutant hyperproinsulinemia. Yet
another syndrome is caused by a mutation at the CA junction
[119]. Impaired prohormone processing leads to the secretion of a
split proinsulin, which has reduced biological activity. Secretion of
mutant insulins or proinsulins in the above patients does not
exclude concomitant induction of chronic ER stress or perturbation
of other organelles as a contributing pathobiological mechanism.
Indeed, we speculate that the variable genetic penetrance of the
above syndromes may be the hallmark of a genetic variant that
modiﬁes long-term survival of b-cells as one component of a
multi-genic trait.
5. Structural implications
Mutations in proinsulin associated with neonatal DM can en-
code amino-acid substitutions not involving cysteine (for review,
see [13]). Within the insulin moiety such mutations have been
found only in the B domain. These substitutions are of structural
interest in relation to the mechanism of protein folding. The muta-
tions occur within the N-terminal segment of the B-chain (residues
B1–B8), central a-helix (B9–B19), and adjoining b-turn (B20–B23).
An overview of key positions in these elements in provided in
Fig. 3B. We discuss these structural elements in turn.
5.1. N-terminal segment
In both the solution structure of insulin [41,120,121] and its
crystallographic T-state [122,123] residues B1–B6 are extended
(asterisk in Fig. 3) whereas B7–B10 comprise a b-turn adjoining
the central a-helix. N-terminal residues contribute to the speciﬁca-
tion of the A7–B7 disulﬁde bridge in vitro [95,96] and to the overall
efﬁciency of proinsulin folding in cell lines [100]. Sites of clinical
mutation (HisB5 and GlyB8; broadly conserved among vertebrate
insulins) have been well characterized [26,76,78,79]. (i) In theFig. 3. Critical sites governing the foldability of proinsulin are widely distributed in
insulin. Asterisk indicates N-terminal segment of the B chain, which promotes
foldability but is dispensable in the mature hormone [100]. Conserved side chains
in or adjoining the C-terminal a-helix of the A chain (LeuA16 and TyrA19; Ca purple
spheres) and at multiple sites in the B chain (Ca red spheres) impair insulin chain
combination in accord with studies of mutant proinsulins in mammalian cell lines
and the distribution of clinical non-cysteine mutations in the insulin gene. Contacts
between the side chains PheB1 and IleA13 (Ca blue spheres), although not well
ordered in the native state, contribute to the cellular foldability of proinsulin.
Residues IleA2, TyrB26, and ProB28 (Ca green spheres) contribute to the structure and
stability of the native state but are not required for efﬁcient disulﬁde pairing in
chain combination. Disulﬁde bridges are as indicated (gold). Coordinates were
obtained from Protein Databank ﬁle 4INS and correspond to molecule 1 of the
classical 2-Zn insulin hexamer [123].native state HisB5 packs within an inter-chain crevice, making
one or more hydrogen bonds to carbonyl oxygens in the A chain.
Diverse substitutions impair chain combination [26]; ArgB5 (which
is observed in some non-mammalian insulins) is by contrast well
tolerated, presumably through formation of analogous inter-chain
hydrogen bonds as visualized in its crystal structure [79]. In mam-
malian cell culture substitution of HisB5 by Asp blocks the folding
and secretion of human proinsulin [26]. (ii) GlyB8 exhibits a
positive u dihedral angle in an insulin monomer and so occupies
a position in the Ramachandran plane ordinarily forbidden to
L-amino acids. Any L-substitution at this site impairs chain
combination whereas yield is enhanced by D-substitutions [76].
Such stereospeciﬁcity implies that the sign of the B8 u angle
contributes to the alignment or misalignment of neighboring CysB7
for disulﬁde pairing.
The solution structure of AlaB5 and SerB8 insulin analogs retain
native-like features and exhibit substantial biological activity de-
spite their reduced foldabilities [26,78]. Decreased thermodynamic
stabilities are observed, presumably due to altered inter-chain
packing (AlaB5) or an unfavorable main-chain conformation (SerB8).
Whereas decreased native-state stability can in principle contrib-
ute to misfolding, it is likely that such perturbations also impose
a kinetic block to disulﬁde pairing and concomitantly decrease
the stability of populated folding intermediates. Evidence for such
kinetic blocks has been provided by cellular studies in which these
and related mutations lead to formation of non-native disulﬁde
isomers [26,78]. Interestingly, the substantial biological activities
of such ‘‘non-foldable’’ analogs [26,78,100] indicate that residues
required for efﬁcient folding may be dispensable in the native state
[124,125].
5.2. Central a-helix
Nascent folding of the B-chain a-helix is observed in equilib-
rium models of the key [A20–B19] folding intermediate [27,40]
and subsequent two-disulﬁde intermediates [44,47,48,91]. In these
models LeuB11 and LeuB15 each contribute to nascent clustering of
non-polar residues. It is thus plausible that clinical mutations at
these sites would impede initial disulﬁde pairing and, should na-
tive disulﬁde pairing be achieved, perturb native structure and
assembly. Ala substitutions at B11 and B15 (although helicogenic
in model peptides) impair the expression and secretion of mini-
proinsulin in S. cerevisciae [93]. Similarly, insulin chain combina-
tion is markedly impaired by interchange of LeuB11 and ValB12,
which would be predicted to perturb tertiary structure without
net change in intrinsic helical potential [73]. It is not clear why
substitution of TyrB16 by His, a clinical mutation that is predicted
to project at the surface of this a-helix [7], may impair folding.
5.3. B20–B23 b-Turn
B-chain super-secondary structure requires a b-turn between
the central a-helix and the neighboring b-strand (residues B24–
B28). This turn contains conserved glycines at B20 and B23, each
of which exhibits a positive u dihedral angle. Whereas Ala substi-
tutions impair the expression of mini-proinsulin in S. cerevisciae
and impede chain combination, efﬁcient disulﬁde pairing (like that
at B8 above) can be rescued by D-amino acid substitutions. A clin-
ical mutation has been found at B23 and is expected to perturb
pairing of cystine A20–B19. The mechanism by which a mutation
at B22 (Arg? Gln; see above) causes MODY is not apparent.
The absence of clinical mutations in the A domain may reﬂect
incomplete sampling of patients, or alternatively, may indicate that
non-cysteine residues in the A domain play a less critical role in
disulﬁde pairing than the B domain. We believe that both explana-
tions have partial validity. On the one hand, studies of the
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A-chain a-helix (residues A1–A8) is not required for disulﬁde pair-
ing [75]. Such dispensability is in accord with a putative structural
pathway in which segmental folding of this a-helix is a late event
(Fig. 2B). On the other hand, the efﬁciency of chain combination is
exquisitely sensitive to substitutions of core residue in the C-ter-
minal A-chain a-helix (LeuA16 and TyrA19; purple spheres in
Fig. 3) [74,126]. Accordingly, we anticipate that continuing genetic
screening of infants and children with antibody-negative DM will
uncover analogous A-domain mutations.
6. Protein folding and induced ﬁt
The evolution of insulin is enjoined by multiple biological con-
straints, including biosynthesis, structure, and function. We imag-
ine that conserved residues may contribute to one or more
essential requirements of viability: foldability in the b-cell, protec-
tion from intra- or extracellular toxic misfolding, self-assembly
within the secretory granule, and receptor binding. The overlap-
ping nature of these constraints may account for the limited se-
quence diversity among vertebrate insulins [123].
Evolutionary constraints may be coincident at some positions
but opposing at others. Studies of stereospeciﬁc B8 analogs, for
example, suggest that at this site kinetic determinants of foldabil-
ity are at odds with conformational requirements of receptor
binding [76,78]. Whereas a positive u dihedral angle (like that of
a D-amino acid) facilitates disulﬁde pairing, a negative dihedral
angle (like that of an L-amino acid) is required for receptor binding
[76,78]. These opposing requirements presumably underlie the
invariance of glycine – the only achiral amino acid – at a site of
conformational change. Indeed, a classical model for the induced
ﬁt of insulin on receptor binding is provided by the TR transition
among zinc insulin hexamers [127]. Although the choreography
of conformational changes seen in the TR transition may pertain
only to hexamers [79], the transition is remarkable for a change
in the sign of the B8 dihedral angle from positive (the foldable
state) to negative (the active state). That B8 provides a hot spot
for mutations causing neonatal DM in turn suggests that induced
ﬁt provides protective mechanism: a premature setting of the B8Fig. 4. Proposed binding surfaces of insulin. (A) Front view and (B) back view. Whereas th
its Site 2-related surface includes hexamer contacts HisB10, ValB18, SerA12, LeuA13 and G
respectively. The structures shown are based on an R crystallographic protomer, which c
of Ref. [76]) but is otherwise unlikely to represent the receptor-bound conformation ofdihedral angle in its active conformation within the b-cell may lead
to toxic misfolding.
The recent co-crystal structure of insulin bound to a fragment of
the IR ectodomain has provided evidence for induced ﬁt within the
C-terminal segment B-chain [128]. As predicted based on studies of
anomalous insulin analogs [120,129,130], detachment of the C-ter-
minal b-strand (residues B24–B28) enables docking of a receptor
a-helix (denoted aCT) against the N-terminal A-chain a-helix.
Such induced ﬁt of the B chain may likewise represent an evolu-
tionary response to the danger of proteotoxicity. Indeed, pre-
detachment of the B-chain b-strand by a chiral perturbation (sub-
stitution by PheB24 by D-Ala) enhances receptor binding at the ex-
pense of increased susceptibility to ﬁbrillation [130]. The aromatic
ring of PheB24 anchors the native b-strand, stabilizes the hydropho-
bic core, contributes to dimerization and hexamer formation [123],
enables induced ﬁt on receptor binding [130], and even further, is
likely to contact the receptor itself [131]. Much remains to be
learned. How induced ﬁt of the B chain is triggered on IR binding,
the nature of the switch at (or near) residue B24, and the contacts
subsequently made by PheB24, PheB25, and TyrB26 were not ad-
dressed in the recent co-crystal structure of a ‘‘micro-receptor’’
model [128].
Understanding the co-evolution of insulin and the IR will re-
quire further structural analysis of their binding interfaces. A
framework is provided by the elegant classiﬁcation of hormone-
binding surfaces in the receptor as Site 1 and Site 2 [132,133].
The cognate IR-binding surfaces of insulin correspond in large part
to its respective dimerization and hexamer-forming surfaces
(Fig. 4) (for review, see [134]). Because the recent co-crystal struc-
ture was restricted to Site 1, it will be of particular interest to ex-
tend such analysis to larger fragments of the ectodomain
containing Site 2 surfaces. Given the ancestral status of insulin sig-
naling in both vertebrates and invertebrates [34–36], an intriguing
possibility exists that distinct evolutionary constraints and histo-
ries are associated with these complementary interfaces. Such an
historical understanding would highlight the relationship between
proinsulin and single-chain homologues (including mammalian
IGF-I and IGF-II), which may have translational implications in can-
cer biology [37,135].e classical receptor-binding surface of insulin engages IR Site 1 (blue; Ref. [132,133],
luA17 (red). The A- and B chains are otherwise shown in light gray and dark gray,
ontains a receptor-active positive phi angle at GlyB24 (in accordance with the results
insulin [128].
1948 M.A. Weiss / FEBS Letters 587 (2013) 1942–1950We imagine in general that conserved side chains in insulin play
multiple distinct roles at each stage of its conformational ‘‘life cy-
cle,’’ representing a remarkable compression of information within
a short protein sequence. It would be of future interest to probe the
range of structures within this life cycle through crystal structures
of insulin–holoreceptor complexes and through solid-state NMR-
based models of non-native insulin aggregates and ﬁbrils.
7. Concluding remarks
The mutant proinsulin syndrome provides an opportunity to
investigate principles of protein folding at the intersection of cell
biology and human genetics. Consistent with classical diffusion-
collision and framework models [136], folding of a globular protein
represents the coalescence of discrete subdomains [137,138].
Whereas funnel-like energy landscapes highlight the role of paral-
lel events in folding [84], evidence for preferred trajectories [139]
has been provided by disulﬁde trapping studies of insulin-related
polypeptides. Characterization of predominant intermediates
promises to enable structural interpretation of many of the clinical
mutations. Sites of mutation reﬂect mechanisms of folding or mis-
folding that may not be apparent in the native state [13].
Foldability of proteins is an evolved property of polypeptide se-
quences [140]. The general threat of toxic misfolding provides a
hidden constraint underlying such evolution. Application of these
principles to insulin promises to connect bench to bedside. An
intrinsic tension between folding-competent and active conforma-
tions of insulin, only partially resolved in the wild-type hormone
by induced ﬁt, may underlie the role of chronic ER stress in the pro-
gression of b-cell dysfunction in Type 2 DM. Molecular dissection
of this progression promises to provide novel therapeutic targets.
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